Compare Peptidream, Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROCE of 36.72%
2
Company has very low debt and has enough cash to service the debt requirements
3
Healthy long term growth as Net Sales has grown by an annual rate of 50.80% and Operating profit at 58.22%
4
Positive results in Dec 25
5
Risky -
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 231,809 Million (Small Cap)
15.00
NA
0.00%
-0.24
-11.07%
4.41
Revenue and Profits:
Net Sales:
5,664 Million
(Quarterly Results - Dec 2025)
Net Profit:
-532 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.85%
0%
-29.85%
6 Months
-28.59%
0%
-28.59%
1 Year
-46.81%
0%
-46.81%
2 Years
-12.94%
0%
-12.94%
3 Years
-34.35%
0%
-34.35%
4 Years
-41.15%
0%
-41.15%
5 Years
-76.79%
0%
-76.79%
Peptidream, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
50.80%
EBIT Growth (5y)
58.22%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.75
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.53
Tax Ratio
28.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
36.72%
ROE (avg)
19.37%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
4.02
EV to EBIT
9.65
EV to EBITDA
8.75
EV to Capital Employed
5.32
EV to Sales
4.37
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
55.15%
ROE (Latest)
27.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
5,663.90
4,313.60
31.30%
Operating Profit (PBDIT) excl Other Income
-392.00
-909.50
56.90%
Interest
58.30
75.00
-22.27%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-531.90
-1,094.80
51.42%
Operating Profit Margin (Excl OI)
-163.30%
-331.00%
16.77%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 31.30% vs 0.07% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 51.42% vs -0.52% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
18,521.20
46,676.50
-60.32%
Operating Profit (PBDIT) excl Other Income
-2,848.00
23,639.90
-112.05%
Interest
363.10
288.10
26.03%
Exceptional Items
21.40
0.70
2,957.14%
Consolidate Net Profit
-3,749.20
15,014.90
-124.97%
Operating Profit Margin (Excl OI)
-268.60%
458.30%
-72.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -60.32% vs 62.57% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -124.97% vs 394.59% in Dec 2024
About Peptidream, Inc. 
Peptidream, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






